Articles
Curated articles from trusted sources covering research, analysis, and news in the psychedelic science and policy space.
25 recent articles
Field Notes #6: Dispatches from D.C. as Three Psychedelics Land at FDA
Field Notes are timely, candid voice notes from our Founder and Editor, Josh Hardman, that give our Pα+ readers a pulse on recent developments in psychedelic drug development, policy, and access.
Breaking: U.S. Government Taps Mark Cuban’s Company to Develop Ibogaine for PTSD; Commits to Fund $20M Real-World Evidence Network
This morning, the U.S. Department of Health and Human Services (HHS) provided an update on two psychedelics-related initiatives during a press conference hosted by its Secretary, RFK Jr.
Robert Rush: Emergency Scheduling, 7-OH, and the War on Research
Attorney Robert Rush joins Joe in Breckenridge to talk about challenging DEA scheduling decisions, from the 2024 DOI and DOC hearing to the emergency scheduling of 7-OH compounds and SR-17018.
We Played Timothy Leary's 1985 Video Game So You Don't Have To
Neşe, Mike, and Normie play and review "Timothy Leary's Mind Mirror," a 1985 video game originally released for Atari 8-bit and later ported to platforms like the Commodore 64 and Apple II.
The Problems We Will Be Lucky to Have
In November 2020, Oregon voters passed the first ballot measure in the country to create a legal, supervised psilocybin program, Measure 109.
Compass Says NDA Will Be Filed Within Two Weeks, Declines to Comment on Usona
This morning, Compass Pathways shared its Q3 2026 results, which included an update on its COMP360 psilocybin for treatment-resistant depression (TRD) new drug application (NDA) submission.
Is It Worth It? What Colorado’s Early Experience With Regulated Psychedelic Care Has the Field Asking, and What To Do About It
Colorado did something genuinely special. Oregon launched the country’s first regulated psilocybin program; Colorado was the first to pair one with statewide decriminalization for personal use.
Usona Files Psilocybin for Depression NDA as Race With Compass Tightens
Nonprofit psychedelic research organisation Usona Institute has completed its submission of a new drug application (NDA) to the U.S.
A Medicalization-Only Model Limits the Psychedelic Experience
Psychedelics have been deeply boxed into a container that seems like the acceptable way that they can be talked about.
FDA Approves NRx’s Preservative-Free Generic Ketamine, but Its Bid to Ban Rivals’ Products Remains Pending
This morning, NRx Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has approved the company’s Abbreviated New Drug Application (ANDA) for its preservative-free ketamine produ...
Australian Bush Doofs and Psychedelic Commercialization (w/ Dr. Sam Douglas & Rich Haridy)
Russell, Mike, and Neşe sit down with journalist Rich Haridy and Dr. Samuel Douglas to discuss bush doofs, Australian psychedelic commercialization, Entheogenesis Australis, Haridy's new book, and mor...
Ten VA Sites, REMS and Ibogaine’s “Uphill Battle”: Feds Weigh In on Psychedelic Access
At the Psychedelic Healthcare Forum, which took place in New York City last Thursday and was co-hosted by Psychedelic Alpha, a panel of federal officials participated in a discussion moderated by POLI...